We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

15 hedge funds and large institutions have $1.71M invested in Cyclo Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more funds holding

Funds holding: 13 → 15 (+2)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

24% less capital invested

Capital invested by funds: $2.23M → $1.71M (-$526K)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$468K
2
Renaissance Technologies
Renaissance Technologies
New York
+$316K
3
VF
Virtu Financial
New York
+$126K
4
Osaic Holdings
Osaic Holdings
Arizona
+$5.1K
5
BlackRock
BlackRock
New York
+$4.06K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$153K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$26.1K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$11.3K
4
State Street
State Street
Massachusetts
-$7.36K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.73K

CYTH Hedge Fund Activity: Q4 2021 in Review

15 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q4 2021, worth a combined $1.71M — down 24% from $2.23M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CYTH positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $468K. The largest seller was UBS Group, cutting an estimated $153K.

  • 15 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q4 2021, up from 13 in Q3 2021.
  • Funds reported $1.71M of Cyclo Therapeutics, Inc. Common Stock stock for Q4 2021, down 24% quarter-over-quarter.
  • 2 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q4 2021 and 0 closed out, a net change of +2 holders.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $468K added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q4 2021 was UBS Group, an estimated $153K sold.

Based on aggregated 13F filings for Q4 2021.